CL2022000340A1 - Formulaciones anti-c5 de alta concentración. - Google Patents
Formulaciones anti-c5 de alta concentración.Info
- Publication number
- CL2022000340A1 CL2022000340A1 CL2022000340A CL2022000340A CL2022000340A1 CL 2022000340 A1 CL2022000340 A1 CL 2022000340A1 CL 2022000340 A CL2022000340 A CL 2022000340A CL 2022000340 A CL2022000340 A CL 2022000340A CL 2022000340 A1 CL2022000340 A1 CL 2022000340A1
- Authority
- CL
- Chile
- Prior art keywords
- formulations
- high concentration
- concentration anti
- cemdisiran
- ahus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962888086P | 2019-08-16 | 2019-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022000340A1 true CL2022000340A1 (es) | 2022-10-07 |
Family
ID=72560889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000340A CL2022000340A1 (es) | 2019-08-16 | 2022-02-09 | Formulaciones anti-c5 de alta concentración. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210046182A1 (OSRAM) |
| EP (1) | EP4013784A1 (OSRAM) |
| JP (2) | JP7813222B2 (OSRAM) |
| KR (1) | KR20220047826A (OSRAM) |
| CN (1) | CN116782876A (OSRAM) |
| AU (1) | AU2020334880A1 (OSRAM) |
| BR (1) | BR112022002831A2 (OSRAM) |
| CA (1) | CA3145621A1 (OSRAM) |
| CL (1) | CL2022000340A1 (OSRAM) |
| CO (1) | CO2022001097A2 (OSRAM) |
| IL (1) | IL290034A (OSRAM) |
| JO (1) | JOP20220030A1 (OSRAM) |
| MX (1) | MX2022001896A (OSRAM) |
| PH (1) | PH12022550167A1 (OSRAM) |
| WO (1) | WO2021034639A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03043B (me) | 2013-03-14 | 2018-10-20 | Alnylam Pharmaceuticals Inc | Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu |
| WO2016145206A1 (en) | 2015-03-10 | 2016-09-15 | Regeneron Pharmaceuticals, Inc. | Aseptic piercing system and method |
| WO2017218515A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| ES2919934T3 (es) | 2017-05-05 | 2022-07-29 | Regeneron Pharma | Autoinyector y procedimientos de uso relacionados |
| MX2020006113A (es) | 2017-12-13 | 2020-08-24 | Regeneron Pharma | Combinaciones de anticuerpos anti-c5 y usos de las mismas. |
| JP2024540086A (ja) | 2021-10-28 | 2024-10-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃ５をノックアウトするためのｃｒｉｓｐｒ／ｃａｓ関連方法及び組成物 |
| USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
| IL318297A (en) * | 2022-07-27 | 2025-03-01 | Cephalon Llc | Anti-TL1A antibody formulations |
| CA3262839A1 (en) * | 2022-07-27 | 2024-02-01 | Cephalon Llc | ANTI-TL1A ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE |
| WO2024092232A1 (en) * | 2022-10-28 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody/c5 irna co-formulations and combination therapies |
| KR20260025363A (ko) | 2023-06-16 | 2026-02-24 | 리제너론 파아마슈티컬스, 인크. | 의료 디바이스 패키징 및 관련 방법 |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
| WO2025075970A1 (en) | 2023-10-02 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | Drug delivery device safety system |
| CN118460651B (zh) * | 2024-07-10 | 2025-03-18 | 凯莱英医药集团（天津）股份有限公司 | 制备Cemdisiran的方法 |
| CN119454939A (zh) * | 2024-11-28 | 2025-02-18 | 北海康成(苏州)生物制药有限公司 | 一种欧莫扑拜单抗原液及其制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| WO1998051278A2 (en) | 1997-05-14 | 1998-11-19 | Inex Pharmaceuticals Corporation | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US8101348B2 (en) | 2002-07-10 | 2012-01-24 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | RNA-interference by single-stranded RNA molecules |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| WO2008086395A2 (en) * | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| NZ588583A (en) | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| BRPI1006519A2 (pt) * | 2009-03-06 | 2016-08-09 | Genentech Inc | formulação de anticorpos |
| TR201811076T4 (tr) | 2009-06-10 | 2018-08-27 | Arbutus Biopharma Corp | Geliştirilmiş lipit formulasyonu. |
| ME03043B (me) | 2013-03-14 | 2018-10-20 | Alnylam Pharmaceuticals Inc | Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu |
| WO2015103438A2 (en) * | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| JP6718379B2 (ja) | 2014-03-20 | 2020-07-08 | インフラルクス ゲーエムベーハー | ウイルス性肺炎治療のためのＣ５ａの阻害剤 |
| WO2017055966A1 (en) * | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| US20190225678A1 (en) | 2016-06-07 | 2019-07-25 | Novartis Ag | Anti-c5 antibody for treating patients with complement c5 polymorphism |
| WO2017218515A1 (en) * | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| WO2018067987A1 (en) * | 2016-10-06 | 2018-04-12 | Amgen Inc. | Reduced viscosity protein pharmaceutical formulations |
| BR112020001703B1 (pt) * | 2017-07-27 | 2024-01-02 | Alexion Pharmaceuticals, Inc | Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma |
| EP3700928A1 (en) * | 2017-10-26 | 2020-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| MX2020006113A (es) * | 2017-12-13 | 2020-08-24 | Regeneron Pharma | Combinaciones de anticuerpos anti-c5 y usos de las mismas. |
-
2020
- 2020-08-14 AU AU2020334880A patent/AU2020334880A1/en active Pending
- 2020-08-14 EP EP20775090.2A patent/EP4013784A1/en active Pending
- 2020-08-14 US US16/993,434 patent/US20210046182A1/en active Pending
- 2020-08-14 MX MX2022001896A patent/MX2022001896A/es unknown
- 2020-08-14 BR BR112022002831A patent/BR112022002831A2/pt unknown
- 2020-08-14 CA CA3145621A patent/CA3145621A1/en active Pending
- 2020-08-14 JO JOP/2022/0030A patent/JOP20220030A1/ar unknown
- 2020-08-14 CN CN202080069383.1A patent/CN116782876A/zh active Pending
- 2020-08-14 PH PH1/2022/550167A patent/PH12022550167A1/en unknown
- 2020-08-14 WO PCT/US2020/046314 patent/WO2021034639A1/en not_active Ceased
- 2020-08-14 KR KR1020227008645A patent/KR20220047826A/ko active Pending
- 2020-08-14 JP JP2022509593A patent/JP7813222B2/ja active Active
-
2022
- 2022-01-23 IL IL290034A patent/IL290034A/en unknown
- 2022-02-02 CO CONC2022/0001097A patent/CO2022001097A2/es unknown
- 2022-02-09 CL CL2022000340A patent/CL2022000340A1/es unknown
-
2025
- 2025-09-12 JP JP2025151837A patent/JP2026003133A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20220030A1 (ar) | 2023-01-30 |
| BR112022002831A2 (pt) | 2022-06-28 |
| WO2021034639A1 (en) | 2021-02-25 |
| EP4013784A1 (en) | 2022-06-22 |
| KR20220047826A (ko) | 2022-04-19 |
| CO2022001097A2 (es) | 2022-03-08 |
| US20210046182A1 (en) | 2021-02-18 |
| CA3145621A1 (en) | 2021-02-25 |
| JP2026003133A (ja) | 2026-01-09 |
| IL290034A (en) | 2022-03-01 |
| JP2022544589A (ja) | 2022-10-19 |
| JP7813222B2 (ja) | 2026-02-12 |
| WO2021034639A4 (en) | 2021-04-15 |
| AU2020334880A1 (en) | 2022-03-24 |
| PH12022550167A1 (en) | 2023-05-08 |
| MX2022001896A (es) | 2022-06-02 |
| CN116782876A (zh) | 2023-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022001097A2 (es) | Formulaciones anti-c5 de alta concentración | |
| DOP2020000128A (es) | Anticuerpos anti-trem2 y métodos relacionados | |
| CL2018003136A1 (es) | Proteínas de unión específica y usos de las mismas. | |
| ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| ECSP18095014A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
| UY34995A (es) | Formulaciones de anticuerpo y proteína | |
| BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
| MX2023014120A (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentradas de baja viscosidad, kits, y metodos. | |
| BR112017016952A2 (pt) | terapia de combinação com fatores de coagulação e anticorpos multiespecíficos | |
| CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
| CL2018002694A1 (es) | Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112) | |
| MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
| BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| MX2021014954A (es) | Composiciones y metodos para la degradacion de proteinas mal plegadas. | |
| DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
| BR112017016636A2 (pt) | formulação líquida estável para anticorpos monoclonais | |
| BR112016014293A2 (pt) | região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune | |
| BR112015021134A2 (pt) | conjugados de fármaco e anticorpo | |
| MX377544B (es) | Composiciones topicas que comprenden un corticosteroide y un retinoide para tratar psoriasis. | |
| ECSP15002095A (es) | Formulación farmacéutica | |
| BR112022005678A2 (pt) | Métodos e composições para o tratamento da retinopatia diabética | |
| MX2021003298A (es) | Métodos para revertir la actividad ticagrelor. |